Title : Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens.

Pub. Date : 2011 Apr

PMID : 21575928






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The type of anti-MM therapy represents a key factor, with a substantially elevated VTE risk in patients treated with the immunomodulatory drugs (IMiDs) thalidomide or lenalidomide in combination with dexamethasone and/or chemotherapy; VTE risk with lenalidomide-dexamethasone is further increased with concomitant erythropoietin. Lenalidomide erythropoietin Homo sapiens